Mylan (MYL -0.7%) receives final approval with 180 days of generic marketing exclusivity from the FDA for its Pioglitazone Tablets, the generic versions of Takeda Pharmaceutical's Actos Tablets and Actoplus Met Tablets. The pills are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Tue, 9:20AM)
at CNBC.com (Mon, 5:20PM)
at Nasdaq.com (Mon, 8:42AM)
at Zacks.com (Fri, 1:30PM)
at Zacks.com (Fri, 8:33AM)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs